Brief: Pharnext completes patient enrollment in Pivotal Phase 3 trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1a
20/12/2016 07:01
Dec 20 (Reuters) - Pharnext Sas PHARN.PA :
* Pharnext completes patient enrollment in international
pivotal phase 3 trial of PXT3003 for Charcot-Marie-Tooth Disease
Type 1a
* Results of PLEO-CMT trial are expected in second half of
2018
Source text for Eikon: ID:nBw8GnDlTa
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development